Shares of Aduro BioTech Inc (NASDAQ:ADRO) have been given an average rating of “Hold” by the ten ratings firms that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $6.50.
A number of research analysts recently issued reports on the company. William Blair lowered Aduro BioTech from an “outperform” rating to a “market perform” rating in a research report on Wednesday, December 18th. HC Wainwright reduced their price objective on Aduro BioTech from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. ValuEngine upgraded Aduro BioTech from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, Cowen lowered Aduro BioTech from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 9th.
Shares of ADRO traded up $0.06 during mid-day trading on Friday, hitting $1.40. The stock had a trading volume of 926,764 shares, compared to its average volume of 965,273. The company’s fifty day simple moving average is $1.18 and its two-hundred day simple moving average is $1.21. The company has a debt-to-equity ratio of 0.39, a current ratio of 7.26 and a quick ratio of 7.26. Aduro BioTech has a fifty-two week low of $0.90 and a fifty-two week high of $4.59.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.03. Aduro BioTech had a negative return on equity of 78.64% and a negative net margin of 544.94%. The business had revenue of $4.80 million during the quarter, compared to analyst estimates of $4.55 million. As a group, analysts forecast that Aduro BioTech will post -0.99 EPS for the current year.
In related news, insider Elsas Andrea Van sold 73,311 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $1.19, for a total transaction of $87,240.09. Following the completion of the transaction, the insider now owns 445,190 shares in the company, valued at approximately $529,776.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 80,880 shares of company stock valued at $96,020 in the last 90 days. Insiders own 5.20% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its position in Aduro BioTech by 234.9% during the 3rd quarter. Virtu Financial LLC now owns 33,901 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 23,778 shares during the period. Wedbush Securities Inc. bought a new stake in Aduro BioTech during the 3rd quarter valued at $39,000. Jane Street Group LLC bought a new stake in Aduro BioTech during the 2nd quarter valued at $56,000. Prudential Financial Inc. raised its stake in Aduro BioTech by 31.4% during the 2nd quarter. Prudential Financial Inc. now owns 38,880 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 9,300 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Aduro BioTech by 121.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 48,923 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 26,833 shares in the last quarter. Institutional investors and hedge funds own 39.58% of the company’s stock.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Recommended Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.